Publication | Closed Access

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Second-line TreatmentHepatologyMedicinePharmacologyPharmacotherapyLiver CancerCancer TreatmentOncologyRadiation OncologyHepatocellular CarcinomaPhase 3RadiologyHealth Sciences